Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
New

SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

for
Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer,
Location: Minneapolis MN
Sponsor: Full-Life Technologies UK Limited

Sex: All

Age: 18+

Code: NCT07873450

Phase 1, Phase 2, Recruiting
New

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

for
Pancreatic Cancer, Skin Toxicities
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07895498

Phase 2, Recruiting
New

A Study of Skipping Radiation Therapy in People With Breast Cancer

for
HER2-positive Breast Cancer, Breast Cancer
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07895511

Recruiting
New

Trial to Evaluate an Educational Video Series for Women in Breast Cancer Treatment

for
Breast Cancer Females, Newly Diagnosed Breast Cancer
Location: Aurora CO, Denver CO, Highlands Ranch CO
Sponsor: University of Colorado, Denver

Sex: Female

Age: 18+

Code: NCT07434817

Recruiting

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

for
Brain Metastases, Cancer (With CNS Involvement)
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT07227610

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

DOAC - Dosing Options in AntiCoagulation Prophylaxis

for
Cancer, VTE (Venous Thromboembolism)
Location: Burlington VT
Sponsor: University of Vermont

Sex: All

Age: 18+

Code: NCT07005024

Phase 3, Recruiting

Decoupling Immunotherapy Toxicity and Cancer Response

for
Tumor, Cardiovascular
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07382752

Recruiting

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

for
Breast Cancer
Location: La Jolla CA
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT07087691

Recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

for
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 12+

Code: NCT06444880

Phase 2, Recruiting

Aromatase Inhibitor Clinical Trial

for
Breast Cancer
Location: Indianapolis IN
Sponsor: National Institute of General Medical Sciences (NIGMS)

Sex: Female

Age: 40 - 70

Code: NCT00228956

Recruiting

Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief

for
Bone Metastases, Prostate Cancer, Breast Cancer,
Location: Hamilton
Sponsor: Hamilton Health Sciences Corporation

Sex: All

Age: 18+

Code: NCT04177056

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: New Haven CT, New York NY, Philadelphia PA, Columbus OH,
Sponsor: Fate Therapeutics

Sex: All

Age: 18+

Code: NCT06241456

Phase 1, Recruiting

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT03941756

Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Boston MA, New York NY, Washington D.C. DC, Durham NC,
Sponsor: OncoC4, Inc.

Sex: All

Age: 18+

Code: NCT06635785

Phase 1, Phase 2, Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for
Hormone Receptor Positive HER-2 Negative Breast Cancer,
Location: Boston MA, Horsham PA, Philadelphia PA, Richmond VA,
Sponsor: Puma Biotechnology, Inc.

Sex: All

Age: 18+

Code: NCT06369285

Phase 2, Recruiting

The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial

for
Heart Failure, Cardiotoxicity, Cancer
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18 - 45

Code: NCT05023785

Recruiting

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

for
Breast Cancer
Location: Chicago IL, La Jolla CA, Sacramento CA
Sponsor: University of Chicago

Sex: Female

Age: 25+

Code: NCT03729115

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

for
Solid Tumors
Location: New Haven CT, Hackensack NJ, Los Angeles CA
Sponsor: Boehringer Ingelheim

Sex: All

Age: 18+

Code: NCT05471856

Phase 1, Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

for
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer,
Location: Miami FL, Pittsburgh PA, Houston TX, Dallas TX,
Sponsor: KaliVir Immunotherapeutics

Sex: All

Age: 18+

Code: NCT06444815

Phase 1, Recruiting

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

for
Advanced or Metastatic Breast Cancer
Location: Nashville TN
Sponsor: Kind Pharmaceuticals LLC

Sex: Female

Age: 18+

Code: NCT05187832

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial